MacroGenics Inc (MGNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.40+3.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MGNX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||
| Revenues | 183.0 | 149.5 | 150.0 | 58.7 | 151.9 | 77.4 | 104.9 | 64.2 | 60.1 | 157.7 | 91.9 | 100.9 | 47.8 | 58.0 |
| Total Revenues | 183.0 | 149.5 | 150.0 | 58.7 | 151.9 | 77.4 | 104.9 | 64.2 | 60.1 | 157.7 | 91.9 | 100.9 | 47.8 | 58.0 |
| Cost of Revenues | — | — | 0.8 | 0.6 | 3.4 | 2.7 | 0.0 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||
| R&D Expenses | 140.4 | 147.2 | 177.2 | 166.6 | 207.0 | 214.6 | 193.2 | 195.3 | 190.8 | 147.2 | 122.1 | 98.3 | 70.2 | 46.6 |
| Operating Income | (34.3) | (72.8) | (110.6) | (168.2) | (121.4) | (202.8) | (131.1) | (177.2) | (171.2) | (22.1) | (60.0) | (20.2) | (38.3) | 0.4 |
| Earnings from Continuing Operations | ||||||||||||||
| Interest Expense | — | 8.5 | 1.1 | 1.4 | 0.0 | 0.0 | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | (75.3) | (66.0) | (9.1) | (119.8) | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | (0.7) | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Income | ||||||||||||||
| Net Income | 60.0 | (74.6) | (67.0) | (0.0) | (119.8) | (202.1) | (129.7) | (151.8) | (171.5) | (19.6) | (58.5) | (20.1) | (38.3) | (0.3) |
| Per Share | ||||||||||||||
| Basic EPS | 0.94 | (1.18) | (1.07) | (0.15) | (1.95) | (3.37) | (2.47) | — | — | — | — | — | (1.40) | (0.04) |
| Diluted EPS | 0.94 | (1.18) | (1.07) | (0.15) | (1.95) | (3.37) | (2.47) | — | — | — | — | — | (1.40) | (0.04) |
| Revenue per Share | 2.88 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 63.6 | 63.2 | 62.6 | 61.9 | 61.4 | 59.9 | 52.4 | — | — | 36.1 | 34.7 | 31.8 | 27.4 | 6.8 |
| Diluted Weighted Avg Shares | 63.6 | 63.2 | 62.6 | 61.9 | 61.4 | 59.9 | 52.4 | — | — | 36.1 | 34.7 | 31.8 | 27.4 | 6.8 |
| Supplemental | ||||||||||||||
| EBITDA | — | (65.7) | (103.0) | (158.6) | (109.6) | (191.5) | (119.1) | (164.9) | (162.0) | (14.9) | (52.4) | (17.3) | (36.5) | 1.6 |
| EBIT | (34.3) | (72.8) | (110.6) | (168.2) | (121.4) | (202.8) | (131.1) | (177.2) | (171.2) | (22.1) | (60.0) | (20.2) | (38.3) | 0.4 |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.